Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by general360on Jan 31, 2019 8:17pm

159 Views

Post# 29304451

RE:RE:RE:Resverlogix Closes $6.6 Million Private Placement with Shenz

Interesting....not quite enuf...what’s the math? Do we currently have about 15m debt left, and half of this 5M USD goes towards the loan, Leaving about 12.5M left? eastern gonna pony up a 1/3? Anyone else? Working on financing this, working on financing I’m sure with Pfizer over across the hallway @zenith for a supposed feb start to their combo trial....dribs and drabs financing....dm said it would cost to get adjudication timeframes down, maybe use some of this moolah to make it happen!!
really down to the wire huh?

Bullboard Posts

Calibre discovers significant gold in Newfoundland